Phase I exploratory clinical study of CD276-targeted chimeric antigen receptor T cells for the treatment of solid tumors
Ontology highlight
ABSTRACT: Interventions: experimental group:CD276-targeted chimeric antigen receptor T cells
Primary outcome(s): SAE rate
Study Design: Single arm
DISEASE(S): Solid Tumors Mainly Include But Are Not Limited To Advanced Lung Cancer, Esophageal Cancer And Colorectal Cancer
PROVIDER: 2703905 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA